FDA Approves Trodelvy®, the First Treatment for Metastatic Triple-Negative Breast Cancer Shown to Improve Progression-Free Survival and Overall Survival

– Trodelvy Significantly Reduced the Risk of Death by 49% Compared with Single-Agent Chemotherapy in the Phase 3 ASCENT Study –

– Trodelvy is Under Regulatory Review in the EU and in the United Kingdom, Canada, Switzerland and Australia as Part of Project Orbis

Continue reading

ASU is among the leaders in patents granted, start-ups launched

Tempe, Ariz., April 8, 2021 Arizona State University, through Skysong Innovations, continues to achieve high rankings in technology transfer metrics. The latest read on this is a survey by the Association of University Technology Managers (AUTM). According to AUTM’s most recent survey (fiscal year 2019), ASU was fourth in patents granted, fourth in startups companies launched and third in inventions disclosed when compared to other universities without a medical school.

Continue reading

Life365 Continues to Build Upon Its Hospital@Home Product Offering with Eat Fit Go Partnership

SCOTTSDALE, AZ, April 6, 2021— Life365, a leading virtual care platform provider, announced its partnership with EAT FIT GO Wellness, a healthy lifestyles company that empowers wellbeing from the inside out with premium, convenient and healthy nutrition. EAT FIT GO specializes in ready to heat and serve healthy prepackaged meals designed to be affordable, convenient and nutritious.

Continue reading

Indoor Drive-Thru Vaccination Site Opens at Dexcom in Mesa

“At Dexcom, our mission is to help improve the health of others, so when asked if we could provide our facility for an indoor mass-vaccination site, we didn’t hesitate,” said Jim Kasselmann, senior director of manufacturing in Mesa for Dexcom. “We are proud to manufacture our products in Mesa, and anytime we can help our local community, that is what we will do.”Continue reading

Regenesis Biomedical Introduces the New Provant Infinity

Scottsdale, Arizona based, Regenesis Biomedical, Inc. has launch the new Provant® Infinity system that is available purchase for home use when prescribed by a health professional.  Outcomes with Provant Therapy are documented in journal articles, white papers, and case reports. Provant relieves pain in several post-operative conditions, including orthopaedic surgery, joint replacement, amputation, rotator cuff repair, back surgery, hernia repair, debridement, hand and foot surgeries, and neuropathy.Continue reading

Banner Alzheimer’s Institute gets $27.5M NIH grant for genetic risk study

Banner Alzheimer’s Institute (BAI) has received a grant expected to total $27.5 million over five years from the National Institute on Aging (NIA), part of the National Institutes of Health (NIH), to further investigate biological and cognitive changes preceding the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease. Led by researchers from Banner and Mayo Clinic in Arizona, the five-year grant will study healthy people with six forms of the apolipoprotein E (APOE) gene, the major genetic risk factor for Alzheimer’s disease, create a shared scientific resource of data and biological samples to support a wide range of future studies, and help to advance the understanding, treatment, and prevention of Alzheimer’s disease.Continue reading

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Abecma is a first-in-class BCMA-directed personalized immune cell therapy delivered as a one-time infusion for triple-class exposed patients with multiple myeloma

In the pivotal KarMMa trial, the majority (72%) of patients achieved rapid, deep and durable responses1

Safety profile of Abecma is well-established and predictable including cytokine release syndrome and neurologic toxicities that are mostly low-grade with early onset and resolution1

 Continue reading

BD to Invest $65 Million for Key Supply Chain Infrastructure in Tucson, Arizona to Increase Resiliency of U.S. Medical Device Supply

TUCSON, Ariz.April 1, 2021 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today it will invest $65 million to construct a state-of-the-art facility in Tucson, Arizona that will be a hub for the company’s supply chain, serving as a final-stage manufacturing and sterilization center.  

Continue reading

NIH clinical trial evaluating Moderna COVID-19 variant vaccine begins

Early-stage trial to evaluate safety and immunogenicity.

In investigational vaccine designed to protect against the B.1.351 SARS-CoV-2 variant has been administered as part of a new Phase 1 clinical trial evaluating the vaccine candidate’s safety and immunogenicity in adult volunteers. The vaccine, known as mRNA-1273.351, was developed by the biotechnology company ModernaTX, Inc., based in Cambridge, Massachusetts. The trial is led and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The trial will enroll approximately 210 healthy adult volunteers at four clinical research sites in the United States that are part of the NIAID-funded Infectious Diseases Clinical Research Consortium(IDCRC).

Continue reading